![Approval indications, dosing, dissociation constant (Ki), and relative... | Download High-Quality Scientific Diagram Approval indications, dosing, dissociation constant (Ki), and relative... | Download High-Quality Scientific Diagram](https://www.researchgate.net/publication/332981417/figure/tbl1/AS:757001101525001@1557494535835/Approval-indications-dosing-dissociation-constant-Ki-and-relative-trapping-capacity.png)
Approval indications, dosing, dissociation constant (Ki), and relative... | Download High-Quality Scientific Diagram
Practical and Scalable Manufacturing Process for the Key Intermediate of Poly(ADP-Ribose) Polymerase Inhibitor Olaparib | ACS Omega
Forest plot of comparison between olaparib maintenance treatment and... | Download Scientific Diagram
![Adverse events in women switching from olaparib capsules to tablets: retrospective observational study of US claims data | Future Oncology Adverse events in women switching from olaparib capsules to tablets: retrospective observational study of US claims data | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon-2020-0142/asset/images/medium/figure1.gif)
Adverse events in women switching from olaparib capsules to tablets: retrospective observational study of US claims data | Future Oncology
![Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial - ScienceDirect Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1470204517304692-gr3.jpg)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial - ScienceDirect
![IJMS | Free Full-Text | Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy IJMS | Free Full-Text | Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy](https://www.mdpi.com/ijms/ijms-22-04203/article_deploy/html/images/ijms-22-04203-g002.png)
IJMS | Free Full-Text | Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy
Practical considerations for clinicians for transitioning patients on maintenance therapy with olaparib capsules to the tablet f
![Adverse events in women switching from olaparib capsules to tablets: retrospective observational study of US claims data | Future Oncology Adverse events in women switching from olaparib capsules to tablets: retrospective observational study of US claims data | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon-2020-0142/asset/images/medium/figure2.gif)
Adverse events in women switching from olaparib capsules to tablets: retrospective observational study of US claims data | Future Oncology
![Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial - ScienceDirect Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1470204517304692-gr1.gif)